Durability score
50/100
Valuation score
38.2/100
Momentum score
59.0/100
Market Capitalization in Cr
39090.1
AVG Broker Target
838.5
PE TTM Price to Earnings
16.2
Aurobindo Pharma Limited    
11 Dec 2017
667.20
0.31%
Economic Times
Among the gainers in the Nifty50 index, Aurobindo Pharma and Tata Consultancy Services climbed up to 3 per cent.
Aurobindo Pharma Limited has an average target of 838.54 from 13 brokers.
Aurobindo Pharma Limited    
04 Dec 2017
667.20
0.31%
Economic Times
Aurobindo is top pick in pharma and Thyrocare Technologies in lab space.
Aurobindo Pharma Limited is trading below it's 30 day SMA of 705.32
Aurobindo Pharma Limited    
26 Nov 2017
667.20
0.31%
Business Line
The stock Aurobindo Pharma (714.5) rules at a crucial level. It finds immediate resistance at 759 and the next crucial one at 817. A close above the latter will re-confirm the long-term positive...
Aurobindo Pharma Limited    
20 Nov 2017
667.20
0.31%
buy
Angel Broking
For 2QFY2018, Aurobindo Pharma (APL) posted numbers slightly higher than expected sales, OPM and net profit fronts. On sales front, the company posted sales of `4,354cr (v/s. `4,200cr expected) v/s. `3,715cr in 2QFY2017, a yoy growth of 17.3%. On the operating front, the EBITDA margin was almost flat at 23.8% (v/s. 25.4% expected) v/s. 23..
Number of FIIs/FPIs holding stock rose by 6 to 775 in Sep 2017 qtr.
Aurobindo Pharma Limited    
19 Nov 2017
667.20
0.31%
Business Line
The company's prospects look promising, with the growing injectables pipeline in the US and better portfolio mix
Aurobindo Pharma Limited    
13 Nov 2017
667.20
0.31%
Khambatta Securities
Aurobindos revenues grew 20.1% q-o-q and 17.5% y-o-y to Rs 44,462 mn in 2Q FY18 exceeding our expectations. Revenue growth was driven by 9.9% y-o-y growth in US and 38.6% y-o-y growth in Europe during the quarter. API business also revived during the quarter and grew at a modest 5.0% y-o-y. Adjusted EBITDA increased 30.6% q-o-q and 20.3% y-o-y to Rs 11,276 mn during 2Q FY18. Adjusted EBITDA margin increased 202 bps q-o-q and 58 bps y-o-y to 25.4% in 2Q FY18, exceeding our expectations, mainly due to lower than expected Cost of Goods Sold as percentage of revenues during the quarter....
Aurobindo Pharma Limited has an average target of 838.54 from 13 brokers.
Aurobindo Pharma Limited    
13 Nov 2017
667.20
0.31%
Nirmal Bang Institutional
Aurobindo Pharma's (APL) revenues and earnings in 2QFY18 were 12.5%/7.9% and 11.3% /14.1% above our/consensus estimates, respectively. The major surprise came from its EU business (Rs1,1135mn) which grew 21.3% QoQ as the timing of tenders coincided across countries and products. However, the quarterly run-rate in the EU is likely to taper over the next few quarters (Rs9,250mn to Rs9,750mn per quarter). Going forward, in FY18 the company expects traction in its US business to be driven by injectables which is expected to significantly accelerate from US$46mn run-rate per quarter to US$65mnUS$70mn run-rate per quarter. Ramp up in injectable sales would be driven by volume gains in pantoprazole injection and tazobactam/piperacillin injection which are under shortage, and new...
Number of Mutual Funds holding stock rose by 12 to 235 in Sep 2017 qtr.
Aurobindo Pharma Limited    
12 Nov 2017
667.20
0.31%
Aurobindo Pharma eyes at least 40% rise in US injectables business in FY18
Aurobindo Pharma eyes at least 40% rise in US injectables business in FY18
livemint
In fiscal year 2016-17, Aurobindo Pharma's US injectable sales rose 67% to $157 million, while in 2015-16, sales were up 39% year-on-year at $95.2 million
Aurobindo Pharma Limited    
11 Nov 2017
667.20
0.31%
HDFC Securities
With major near-term launches priced in, we downgrade our rating to NEUTRAL, with a revised TP of Rs 800 (16x Sep-19E). The launch of gRenvela where Aurobindo Pharma (ARBP) was the first to market, provided a significant boost in 2QFY18. Revenue grew 18% YoY to Rs 43.9bn, EBITDA margin was up 57bps at 25.4%, and PAT jumped 28% YoY to Rs 7.8bn. However, multiple generic players have since launched gRenvela tablets, leading to substantial price erosion and lower market share for ARBP. We expect US sales to taper down for the next few quarters, as visibility on similar lucrative launches is low.
Number of FIIs/FPIs holding stock rose by 6 to 775 in Sep 2017 qtr.
Aurobindo Pharma Limited    
11 Nov 2017
667.20
0.31%
Business Standard
Strong US product pipeline to help sustain the performance
  • Stock Price (677.50) crossed below 200 Day SMA (686.83) on 12 December, 2017
  • Stock Price (672.50) crossed below 150 Day SMA (693.72) on 01 December, 2017
  • Centrum Broking released a Buy report for Aurobindo Pharma Limited with a price target of 1030.0 on 22 Nov, 2017.
  • Week Change by -10.93% (Crossed threshold 10%) on 14 November, 2017
  • Stock Price (712.20) crossed below 100 Day SMA (728.48) on 13 November, 2017
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Nov. 21, 20171.50INTERIM-
June 8, 20171.25INTERIM-
Nov. 24, 20161.25INTERIM-
June 9, 20160.70INTERIM-
Feb. 18, 20160.70INTERIM-
All dividends by AUROPHARMA
Ex-Date Dividend Bonus Ratio Record Date
July 20, 20151:1July 21, 2015
All bonuses by AUROPHARMA
Ex-Date Dividend Old FVNew FV Record Date
Feb. 10, 201151Feb. 11, 2011
All splits by AUROPHARMA